Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (231-240 of 343) with videos related to

Pageof 35
Sort By:
The Journal of Rheumatology|March 2, 2022
Young-GRAPPA at the Annual GRAPPA Meeting: Presentation of a New Group Within GRAPPA and Its VisionLeonieke J J van Mens, Gizem Ayan, Laura C Coates, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Trials|March 5, 2021
Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study designInes Rombach, William Tillett, Deepak Jadon, et al.
Clinical Pharmacology and Therapeutics|October 23, 2025
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do MatterAmy C D Peeters, Maike H M Wientjes, Wieland D Müskens, et al.
The Journal of Rheumatology|February 3, 2020
Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic ArthritisYing Ying Leung, Ana-Maria Orbai, Alexis Ogdie, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic ArthritisSarah M Yazji, Philip S Helliwell, Andra Balanescu, et al.
The Journal of Rheumatology|March 15, 2026
Further validation of a questionnaire to assess flare in psoriatic arthritis: determination of cut-off and longitudinal changePhilip S Helliwell, Juan D Cañete, Laura C Coates, et al.
Annals of the Rheumatic Diseases|September 17, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX studyPhilip J Mease, Christopher T Ritchlin, Laura C Coates, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter StudyWilliam Tillett, Oliver FitzGerald, Laura C Coates, et al.
RMD Open|February 2, 2026
Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT studyHelena Marzo-Ortega, Philipp Sewerin, Carlo Selmi, et al.
Pageof 35

Showing results (231-240 of 343) with videos related to

Sort By:
Pageof 35
The Journal of Rheumatology|March 2, 2022
Young-GRAPPA at the Annual GRAPPA Meeting: Presentation of a New Group Within GRAPPA and Its VisionLeonieke J J van Mens, Gizem Ayan, Laura C Coates, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Trials|March 5, 2021
Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study designInes Rombach, William Tillett, Deepak Jadon, et al.
Clinical Pharmacology and Therapeutics|October 23, 2025
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do MatterAmy C D Peeters, Maike H M Wientjes, Wieland D Müskens, et al.
The Journal of Rheumatology|February 3, 2020
Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic ArthritisYing Ying Leung, Ana-Maria Orbai, Alexis Ogdie, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic ArthritisSarah M Yazji, Philip S Helliwell, Andra Balanescu, et al.
The Journal of Rheumatology|March 15, 2026
Further validation of a questionnaire to assess flare in psoriatic arthritis: determination of cut-off and longitudinal changePhilip S Helliwell, Juan D Cañete, Laura C Coates, et al.
Annals of the Rheumatic Diseases|September 17, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX studyPhilip J Mease, Christopher T Ritchlin, Laura C Coates, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter StudyWilliam Tillett, Oliver FitzGerald, Laura C Coates, et al.
RMD Open|February 2, 2026
Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT studyHelena Marzo-Ortega, Philipp Sewerin, Carlo Selmi, et al.
Pageof 35